Group 2 Innate Lymphoid Cells Attenuate Inflammatory Arthritis and Protect from Bone Destruction in Mice

Graphical Abstract

Highlights

- ILC2s in RA are increased in blood and synovial tissue compared with healthy controls
- ILC2s in RA inversely correlate with disease activity
- Artificially elevated ILC2 levels significantly attenuated arthritis in animal models
- ILC2s attenuated arthritis in an IL-4/13-dependent manner

Authors

Yasunori Omata, Michael Frech, Tatjana Primbs, ..., Stefan Wirtz, Georg Schett, Mario M. Zaiss

Correspondence
mario.zaiss@uk-erlangen.de

In Brief

The role of ILC2s in the initiation phase of inflammatory arthritis has remained unclear. Omata et al. demonstrate that the ILC2-derived IL-4/13 decrease pro-inflammatory cytokine secretion by macrophages, thereby attenuating arthritis.

Omata et al., 2018, Cell Reports 24, 169–180

July 3, 2018 © 2018 The Authors.
https://doi.org/10.1016/j.celrep.2018.06.005
Group 2 Innate Lymphoid Cells Attenuate Inflammatory Arthritis and Protect from Bone Destruction in Mice

Yasunori Omata, Michael Frech, Tatjana Primbs, Sébastien Lucas, Darja Andreew, Carina Scholtyssek,
Kerstin Sarter, Markus Kindermann, Nataliya Yeremenko, Dominique L. Baeten, Nico Andreas, Thomas Kamradt,
Aline Bozec, Andreas Ramming, Gerhard Kröne, Stefan Wirtz, Georg Schett, and Mario M. Zaiss

INTRODUCTION

Innate lymphoid cells (ILCs) are rare immune cells defined by their lack of T cell receptors and absence of lineage markers. Nevertheless, they share many functional similarities with T cells. Although T cells outnumber ILCs by far, ILCs are often the first responders, initiating critical immune responses before adaptive immunity starts. ILCs may therefore play a role in the initiation of arthritis, but functional data on ILCs in arthritis are limited to date. Recent work suggested that a specific form of ILCs, ILC3s, which are a source of IL-17 and IL-22, reside in entheses and are enriched in the joints of patients with spondyloarthritis (Ciccia et al., 2012, 2015; Cuthbert et al., 2017; Leijten et al., 2015). Some analyses have also been carried out in rheumatoid arthritis (RA) patients showing that ILC1 and ILC3 reside in the synovial fluid of RA patients (Dalbeth and Callan, 2002; Koo et al., 2013; Ren et al., 2011) and are positively correlated with clinical disease activity (Koo et al., 2013). In one study of subjects with pre-clinical RA, in which the authors did not distinguish between ILC1 and ILC2, the combined ILC1/2 population presented a larger proportion of ILCs in lymph nodes compared with healthy controls, suggesting that ILCs may be involved in RA from the very beginning (Rodríguez-Carrio et al., 2017). Apart from these descriptive studies on ILC1 and ILC3, data on the function of ILCs in RA are rare. Recently, we showed that ILC2s induce the resolution of arthritis via the production of IL-9, which in turn restores the suppressive capacity of Tregs, enabling them to suppress chronic inflammation (Rauber et al., 2017). In this context, studies of ILC2s are highly interesting, as they are linked to Th2 cell activation, which has recently been described as a regulatory pathway in RA (Chen et al., 2016).

In this study we addressed the role of ILC2s in the initiation phase of RA. On the basis of the cytokine signature and the induction of type 2 immune responses that lead to enhanced tissue repair, along with control of inflammation (Chen et al., 2016; Gause et al., 2013), we hypothesized that ILC2s have an attenuating effect on RA. To test this concept, we investigated different ILC2 gain- and loss-of-function models during inflammatory arthritis. We could show that ILC2 numbers are increased both in RA patients and in inflammatory arthritis mouse models. In two settings of genetically reduced ILC2 numbers, arthritis was exacerbated, while therapeutic enhancement of ILC2 function had a protective effect on RA. This regulatory action of ILC2s was dependent on their capacity to secrete IL-4/13, as IL-4/13−/− ILC2s failed to attenuate arthritis after adoptive cell transfer. Mechanistically, ILC2-derived IL-4/13 significantly suppressed IL-1β section by macrophages, and it was shown that both IL-1β and macrophages are key players driving early clinical symptoms in SIA and RA (Ji et al., 2002; Misharin et al., 2014). This mechanism was critical only during the initiation phase of arthritis.
arthritis, as therapeutically adoptive ILC2 transfer at later time points also failed to attenuate arthritis. Our data thus reveal essential regulatory functions of ILC2s in inflammatory arthritis.

RESULTS

ILC2s Are Increased in RA Patients and Inversely Correlate with Disease Activity

We first assessed ILC2 numbers in peripheral blood samples from RA patients and healthy controls using flow cytometry. ILC2s were identified as lineage-negative (CD3, CD11c, CD123, CD14, CD34, TCRαβ, TCRγδ, CD303, and CD94) CD127+ CD161+ CRTH2+ GATA3+ cells. Although circulating ILC2s were low in healthy controls, their relative and absolute numbers were elevated in RA patients (Figure 1A). When analyzing RA patients, who had elevated ILC2s (>0.7% of leukocytes), ILC2s were inversely correlated to disease activity as measured by DAS28-ESR scores (Figure 1B). Furthermore, when comparing RA patients with inactive (DAS28-ESR < 3.2) versus active (DAS28-ESR ≥ 3.2) disease, ILC2s were significantly higher in RA patients with inactive disease (Figure 1B). Of note, ILC2s were also detected in the synovial tissue of RA patients with a tendency toward elevated numbers compared with peripheral blood samples taken from the same patients (Figure 1C). Hence, the observed increase in RA patients together with their presence in the synovial tissue highlights their possible systemic as well as local involvement during RA.

ILC2s Are Induced during Experimental Arthritis and Primarily Secrete IL-4

Next, two different arthritis mouse models, namely the K/BxN serum transfer (SIA; passive transfer of antibodies) and the collagen-induced arthritis (CIA) model (active immunization with chicken collagen type II followed by collagen boost injection 21 days later), were analyzed for the dynamics of ILC2 regulation during arthritis. ILC2 numbers, identified as lineage-negative (CD3ε, CD4, CD8α, CD11b, and CD16) CD90.2+ KLRG1+ ST2+ GATA3+, rapidly increased after disease onset in SIA (Figure 1D) and CIA (Figure 1E). Along with the initiation phase of arthritis IL-4-competent ILC2s accounted for the most significant proportion of ILC2s, followed by IL-5-competent and IL-13-competent ILC2 in descending order (Figures 1D and 1E). Although we observed a significant increase of ILC2s in the SIA model, only Th1 (CD4+ T-bet+) cells increased at a comparable rate, whereas Th2 (CD4+ GATA3+), Th17 (CD4+ RORγt+), and Tregs (CD4+ Foxp3+) were not significantly changed (Figure 1F).

To further confirm the presence of ILC2s in the inflamed joints, we analyzed synovial tissue using fluorescence-activated cell sorting (FACS) and could show that ILC2s can be found in the blood and the synovial tissues when clinical signs of arthritis were fully developed at 8 days post-SIA induction (Figure 1G). In the bone marrow, where ILC2s develop from their progenitors, IL-4-competent ILC2s were significantly upregulated and accounted for more than 80% of total ILC2s already on day 4 post-SIA induction (Figure 1H). Interestingly, their numbers in synovial tissue increased at later time points, at 8 days post-SIA induction (Figure 1H), possibly showing their early accumulation in the bone marrow, followed by their later egress to the synovial tissue. Also, we investigated ILC2s immunohistochemically at 8 days post-SIA induction in the inflamed joints by using bone marrow chimeras with RoraCre/TdTomefl/fl reporter as donor mice and wild-type as recipient mice (to reduce the strong fluorescence of radio-resistant cells in the RoraCre/TdTomefl/fl mice) after SIA induction. There, we could show the presence of ILC2s, identified according to the expression of RORα as the essential transcription factor besides GATA3 (Halim et al., 2012; Möösberg et al., 2012) in combination with IL-17RB in the inflamed arthritis tarsal joints of the hind paws (Figure 1I). These results show that similar to RA patients, ILC2s are upregulated in two different arthritis mouse models both systemically and locally in the inflamed joints.

Reduced ILC2 Numbers in Mice Exacerbate Arthritis and Bone Destruction

To examine the functional role of ILC2s, we investigated two independent mouse strains showing genetically reduced ILC2 numbers, namely RoraCre/Gata3fl/fl (Figures 2A–2F) and Tie2cre/RoraCreGata3fl/fl mice (Figures 2G–2L). First, RoraCre/Gata3fl/fl mice showed higher arthritic scores after induction of CIA compared with littermate control mice RoraCre/Gata3fl/fl (wild-type [WT]) (Figure 2B). Exacerbated arthritis scores in RoraCre/Gata3fl/fl mice were associated with increased bone erosions and inflamed areas in the affected paws analyzed by histomorphometry (Figures 2C and 2D). Systemically, RoraCre/Gata3fl/fl mice showed no obvious difference in systemic bone mass, presented as bone volume per total volume (BV/TV), but significant upregulated osteoclast numbers (Figure 2E). In addition, there was no difference in Th17 and Treg numbers (Figure 2F) and T cell-derived serum cytokine levels, except for reduced IL-22 serum concentrations (Figure S1A), while a significant increase in CD11b+F4/80+ macrophages, a well described source of pro-inflammatory cytokines like IL-1β, was detected (Figure 2G).

Also Tie2cre/RoraCreGata3fl/fl mice showed exacerbated arthritis after SIA induction compared to littermate Tie2cre/RoraCreGata3fl/fl (WT) control mice (Figures 2H and S2A) along with significantly reduced ILC2 numbers (Figures 2I and 2J). Of note, among the analyzed cytokines secreted by ILC2s in Tie2cre/RoraCreGata3fl/fl mice, IL-4, together with IL-5, were the most prominent ones when detected by intracellular FACS analysis (Figure 2I). To investigate if other lymphocyte subsets or cytokines are involved, we analyzed Treg, Th1, Th2 and Th17 cell populations and T cell-derived cytokines and could not detect any differences at day 8 post-SIA induction (Figures 2K, 2L, and S1B). These data support a functional role of ILC2s in arthritis, which is related to immune regulation rather than activation, as two mice strains with genetically reduced ILC2 numbers showed exacerbated clinical arthritis.

Systemic In Vivo Induction of ILC2s Attenuate Arthritis and Bone Destruction

IL-25 and IL-33 were shown to elicit ILC2s (Fallon et al., 2006; Moro et al., 2010; Neill et al., 2010; Salimi et al., 2013), and recently a role of IL-33 in the egress of ILC2s from the bone marrow has been reported (Ster et al., 2018). Therefore, we used the mini-circle (mc) technology (Liu et al., 1999; McHedlidze et al., 2013) to systemically overexpress IL-25 and IL-33 (Figure S2B) in order to analyze if increased ILC2 numbers...
Figure 1. Group 2 Innate Lymphoid Cells Are Increased in Rheumatoid Arthritis Patients and Inflammatory Arthritis Models

(A) Flow cytometry analysis of GATA3+ ILC2s in the peripheral blood. ILC2s identified as lineage-negative (CD3, CD11c, CD14, CD19, CD34, CD123, TCRβ, TCRγδ, CD393, FcεR1, and CD303) CD127+ CD161+ CRTH2+ and GATA3+ cells in healthy controls (n = 21) and RA (n = 59) patients. Shown as percentages in total cells (left) and absolute numbers per milliliter (right).

(B) Left: correlation plot between ILC2 and disease activity demonstrated by disease activity score 28 (DAS28) based on erythrocyte sedimentation rate (ESR) in RA patients with elevated ILC2s. Right: ILC2 numbers in inactive (DAS28-ESR < 3.2) and active (DAS28-ESR ≥ 3.2) RA patients.

(C) ILC2 numbers in human peripheral blood and human synovial tissue from the same patients.

(D) ILC2s in serum-induced arthritis (SIA) and (E) collagen-induced arthritis (CIA). Flow cytometry analysis of ILC2s in the spleen identified as lineage-negative (CD3e, CD4, CD8a, CD19, CD11b, and CD161) CD45+, CD90.2+, ST2+, KLRG1+, GATA3+, with additional intracellular staining for IL-4, IL-5, and IL-13 expression. Results are representative of two independent experiments.

(F) Flow cytometry analysis of splenic Th cell subsets in SIA.

(G) Comparison of ILC2 numbers in the peripheral blood and synovial tissues in SIA.

(H) Flow cytometry analysis of ILC2s in the bone marrow and synovial tissue in SIA.

(I) Immunohistological detection of ILC2s in the joints of wild-type irradiated recipient mice transferred with Roraγt+ Tdtomato+/+ bone marrow donor mice and induced for SIA.

Representative data are from one of two independent experiments. Data are expressed as mean ± SEM. *p < 0.05 and **p < 0.001. Statistical analyses were performed by comparing against control or day 0 samples in each analysis group.
mitigate arthritis. IL-25/33 mc-treated mice showed significantly attenuated arthritis compared with control mice (Figures 3A and S2C), along with systemically increased total ILC2 numbers (Figure 3B). Of note, IL-4- and IL-5-competent ILC2s represented the highest proportion of ILC2s (Figure 3B). Locally, immunohistological and FACS analysis of the paws and the synovial tissues,
respectively, showed significantly increased ILC2 numbers following IL-25/33 mc treatment (Figure 3C). Histomorphological analysis of the paws revealed reduced bone erosions along with less inflammation in IL-25/33 mc-treated mice after SIA induction on day 14 (Figure 3D). Also systemically, BV/TV was increased, and osteoclast numbers per analyzed bone surface were reduced in tibial sections (Figure 3E). Analysis of Treg, Th1, and Th2 cells revealed no significant difference, whereas Th17 cells were surprisingly increased in IL-25/33 mc-treated mice at 14 days post-SIA induction (Figures 3F and 3G). Serum cytokines were unchanged (Figure S1C). To further strengthen the regulatory role of ILC2 gain of function during SIA, IL-2/IL-2 antibody complex (IL2c) treatment was used (Pelly et al., 2016). IL2c treatment resulted in significantly attenuated arthritis scores compared with untreated controls (Figures 4A and S2D) as well as significantly increased ILC2 numbers in the spleen (Figure 4B) and locally in the affected, inflamed synovial tissue (Figure 4C). Inflamed areas in the joints (Figure 4D), bone erosions, and osteoclast numbers in the joints (Figure 4E) were reduced upon IL2c treatment, while bone volume was improved, confirming our previous observations in ILC2 induction experiments by IL-25/33 mc treatment. However, in the IL2c-treated mice, we could not observe any significant changes in Treg, Th1, Th2, or Th17 cell populations or serum cytokines (Figures 4F, 4G, and S3A). Of note, IL2c treatment in Tie2cre/Rorafl/fl mice failed to attenuate arthritis scores compared with untreated control Tie2cre/Rorafl/fl mice expansion, these results strongly suggest that ILC2s have a positive role on arthritic disease severity.

**Transfer of ILC2s Attenuates Arthritis and Bone Destruction**

Furthermore, in order to have direct proof that ILC2s alone can attenuate arthritis, we performed adoptive transfer experiments with sorted and ex vivo expanded ILC2s (Duerr et al., 2016) transferred into WT recipient mice before SIA was induced (Figure 5). ILC2 transfer into WT mice significantly reduced arthritis (Figure 5A). We also found systemically increased ILC2 numbers in the spleen, with IL-4-competent ILC2s contributing to more than 60% of total analyzed ILC2s (Figure 5B) as well as locally in the affected, inflamed synovial tissue by FACS analysis (Figure 5C). Similar to the results obtained by systemic induction of ILC2s (Figures 3 and 4), adoptive transfer of ILC2s reduced bone erosions and inflamed areas in the affected paws 14 days after SIA induction (Figure 5D). Even systemically, we observed an increase in BV/TV and a concomitant decrease in osteoclast numbers per analyzed bone surface (Figure 5E). Furthermore, WT ILC2s were adoptively transferred also into IL-7R−/− recipient mice (Figures 5F–5J), as it was shown that IL-7 is essential for ILC2 differentiation (Moro et al., 2010; Robinette et al., 2017; Vonarbourg and Diefenbach, 2012). The observed anti-arthritic effect after adoptive WT ILC2 transfer into WT recipient mice was even more pronounced in IL-7R−/− recipient mice (Figure 5F). Similar to WT recipient mice, IL-7R−/− recipient mice...
showed increased ILC2 numbers (Figures 5G and 5H), and decreased inflamed area and bone erosions (Figure 5I) in the affected paws as well as increased systemic BV/TV along with a reduction in osteoclast numbers in the tibia (Figure 5J). Again, as IL-7R−/−C0−/−C0− are not completely lacking ILC, and IL-7 signaling might affect other potentially important cell types as well, we additionally performed the SIA mouse model in IL-7R−/−C0−/−C0− mice without adoptively transferred ILC2s. Surprisingly, we observed per se improved clinical arthritis scores (Figures S4A and S4B) but unchanged Treg, Th1, and Th2 immune cells responses, whereas Th17 cells were significantly upregulated in IL-7R−/−C0−/−C0− mice compared with WT controls (Figures S4C and S4D). Nevertheless, adoptive WT ILC2 transfers further attenuated the observed phenotype in IL-7R−/− mice. These results corroborate that the observed phenotypes after in vivo ILC2 expansion were independent of other potential target cells types, as the induction of ILC2s and the adoptive transfer of these cells yielded very similar results.

**IL-4/13-Competent ILC2s Are Essential for the Observed Attenuating Effects**

Because in our experiments shown so far, IL-4-competent ILC2s represented the highest proportion of total ILC2, we adoptively transferred ILC2 from IL-4/13−/− mice and compared them with WT ILC2s (Figure 6). Interestingly, adoptive transfer of IL-4/13−/− ILC2s did not show significant attenuation of clinical arthritis, whereas WT ILC2s did (Figures 6A and S2F). Again, FACS analysis revealed the successful ILC2 transfer, as both ILC2 recipient groups showed increased ILC2 numbers compared with control group that did not receive ILC2s (Figure 6B). Serum cytokine analysis on day 8 post-SIA induction showed significant upregulated IL-4 concentrations in WT ILC2-transferred recipient mice (Figure 6C). The levels of pro-inflammatory IL-1β and TNFα were reduced, although non-significantly, after transfer of WT ILC2s and even significantly increased after IL-4/13−/− ILC2 transfer (Figure 6D). Other investigated effector serum cytokines, except IL-6 at day 4, remained unchanged at day 4 and day 8 post-SIA induction (Figures S3B and S3C). Interestingly, Treg numbers were only significantly increased in WT ILC2 recipient mice (Figure 6E), whereas the Th1 cells were upregulated only in IL-4/13−/− ILC2 recipient mice and Th2, Th17 remained unchanged in both (Figure 6F). Furthermore, we investigated the potential therapeutic effect of ILC2 adoptive transfers (either from WT or IL-4/13−/− donor mice) by transferring ILC2s during established disease 4 days after the induction of SIA (Figure 6G). In line with our hypothesis that IL-4/13 play an important role in the initiation phase of SIA, we did not observe any clinical improvement in the later stages of the disease. Together, these data show the critical involvement of ILC2-derived cytokines IL-4/13 in the initiation phase of arthritis.

**IL-4/13-Competent ILC2s Suppress Pathogenic RA Cytokines IL-1β and TNFα**

On the basis of the reduced IL-1β and TNFα serum cytokine levels after ILC2 transfers, we further investigated the potential of ILC2s to affect IL-1β and TNFα cytokine secretion in vitro.
Therefore, bone marrow-derived macrophages (BMDMs) were stimulated with lipopolysaccharide (LPS) ± additional ATP in the presence or absence of ILC2s from WT or IL-4/13−/−/− mice. As shown in Figure 7A, WT ILC2s significantly suppressed IL-1β secretion. This was dependent on IL-4/13, as IL-4/13−/−/− ILC2s were lacking this suppressive effect (Figure 7A). Although significant, the effect on TNFα (Figure 7B) was only mild, and no effect on IL-6 cytokine concentrations was observed (Figure 7C). These results show that ILC-derived IL-4/13 is capable of blocking IL-1β, a key effector cytokine in SIA (Ji et al., 2002) secreted by macrophages, which are the essential effector cells in SIA (Misharin et al., 2014).

DISCUSSION

Recent studies have elucidated the role of ILCs in inflammatory diseases, demonstrating their multi-functionality in disease exacerbation and prevention. For instance, ILC1 protect roles in the expulsion of helminths (Fallon et al., 2006) and in type 2 immunopathology after allergen exposure in the lungs (Halm et al., 2012). Importantly, type 2 immune responses have previously shown to exert regulatory effects on arthritis (Chen et al., 2016). Recently, Rauber et al. (2017) identified IL-9 as one regulator for the resolution of arthritis by showing that IL-9-secreting ILC2s restore the suppressive capacity of Tregs, enabling them to dampen already established chronic inflammations. In this study, we report on the fast and early increase in IL-4/13+ ILC2s and demonstrate their importance on the initiation phase of arthritis rather than the resolution of established chronic inflammatory arthritis. We can show that IL-4/13+ ILC2s are beneficial in the early initiation phase.

ILC2s rapidly increased after induction of arthritis and could be detected in the synovial tissue of two different arthritis models (SIA and CIA) as well as in human RA patients. Functional experiments revealed that genetically decreased ILC2 numbers in Rora−/−Gata3−/− or Tie2−/−/RORA−/− mice exacerbated arthritis, mice against Toxoplasma gondii infection (Klose et al., 2014), but they were also linked to pathogenic mucosal inflammation (Bernink et al., 2013). Similarly, ILC3 were reported to fuel intestinal inflammation (Pearson et al., 2016) but at the same time have been shown to be involved in wound healing after skin injury (Li et al., 2016). Although ILC3 and potentially also ILC1 may indeed have pro-inflammatory properties in arthritis, particularly related to IL-17 and IL-22 production and their role in spondyloarthritis, the effect of ILC2s on arthritis seems to be substantially different. ILC2s play prominent...
while in vivo gain-of-function models, such as IL-25/33 mc or IL2c treatment, consistently attenuated arthritis and mitigated bone destruction. Although IL-25/33 mc and IL2c treatments both provide strong support for ILC2s being regulatory cellular mediators in arthritis, additional effects not directly based on ILC2s cannot be excluded. For instance, it was shown that IL2c enhances Arg1 expression (Pelly et al., 2016), IL-25 induces Th2 responses (Fort et al., 2001), and IL-33 increases Treg frequency (Biton et al., 2016; Schiering et al., 2014), upregulates FcgRIIB expression on macrophages (Anthony et al., 2011), and suppresses osteoclast numbers (Zaiss et al., 2011). Of note, recently it was shown that IL-33 is important for the egress of ILC2s from the bone marrow, further supporting our attenuating effects of IL-25/33 mc treatment on arthritis scores (Stier et al., 2018). Also, differences of ILC2s in the capacity to induce Tregs might evolve of diverse stimuli used to increase ILC2 numbers compared with adoptive transfers of mature, ex vivo pre-activated ILC2s. To exclude non-ILC2-mediated effects of IL-25/33 mc and IL2c treatments, we performed adoptive transfer experiments of sorted ILC2s and found that these cells directly attenuated arthritis scores. This effect was dependent on the capacity of ILC2 to secret IL-4/13, as IL4/13−/− ILC2s failed to attenuate arthritis. IL-4/13+ ILC2s were critical during the initiation phase of arthritis, as adoptive transfer of ILC2 at later time points failed to affect arthritis. Beside the prominent downregulation of IL-1β by IL-4/13+ ILC2s, which is a key effector cytokine in arthritis (Ji et al., 2002; Lamacchia et al., 2012), IL-4 itself acts as a regulatory cytokine in arthritis, as it fosters Th2 cell commitment, induces Ig class switching to the Th2-associated isotypes IgG1 and IgE (Nelms et al., 1999), and has the ability to suppress synoviocyte proliferation (Dechanet et al., 1993). In accordance, most (Horsfall et al., 1997; Joosten et al., 1997; Myers et al., 2002) but not all (Ohmura et al., 2005) studies showed that IL-4 has attenuating effects on arthritis. Studies of IL-13 and arthritis are limited, and although IL-13 is found in RA (Liu et al., 2016; Silos-Santiago et al., 2016; Tokayer et al., 2002), only one study addressed its functional role by showing that IL-25/IL-13 has an attenuating effect on arthritis (Liu et al., 2016; Silos-Santiago et al., 2016; Tokayer et al., 2002). Taken together these previous works and our findings suggest that a key regulatory factor in arthritis is the generation of IL-4/13-competent ILC2s.

In summary, we identified ILC2s as a regulatory cell lineage in the early development of arthritis. Enhancement of ILC2 numbers may therefore be a method to effectively block the development of this severe inflammatory joint disease.

**EXPERIMENTAL PROCEDURES**

**Mice**

C57BL/6J mice as well as DBA/1 and BALB/cJRj mice were purchased from The Jackson Laboratory and were acclimated for 1 week, followed by a
Figure 7. IL-4/-13-Competent ILC2s Suppress IL-1β Secretion in Macrophages
WT or IL-4/-13–/– ILC2s were co-cultured with bone marrow–derived macrophages (BMDMs) in vitro with 60,000 BMDMs and 30,000 ILC2/well. The supernatant was analyzed after 6 hr stimulation with LPS (0.1 ng/μL) ± ATP (5 mM). (A–C) IL-1β (A), TNFα (B), and IL-6 (C) measured by ELISA in the culture supernatants. Representative data are from one of two independent experiments. Data are expressed as mean ± SEM. *p < 0.05.

2 week co-housing period before the experiments started. B6-Ptprca-Pep3b/B6.Ptprca-Pep3b/J (IL-7Rα−/−) mice were kindly provided by Immo Prinz from Medizinische Hochschule (Hannover, Germany). BALB/c/Jr IL-4/4 knockout mice were kindly provided by David Vöhringer, Department of Infection Biology, Institute for Medical Microbiology, Immunology and Hygiene, Friedrich-Alexander University Erlangen-Nürnberg (Erlangen, Germany) (Turqueti-Neves et al., 2015). Rorafl/flGata3fl/fl mice and Tie2Cre fl/fl mouse were kindly provided by Stefan Wirtz, Department of Internal Medicine 1, University of Erlangen-Nürnberg (Erlangen, Germany). All mice were maintained under specific pathogen-free conditions at Prähelisches Experimentelles Tierzentrum (PETZ) (Erlangen, Germany). The local ethics committee of the government of Mittelfranken approved all experiments.

Experimental Model of Arthritis
For CIA, arthritis was induced in 8-week-old female BALB/c mice and BALB/cJr mice were treated with 4 μg of mc vector of IL-25 and IL-33 hydrodynamically 5 days before the initiation of arthritis (SIA), as described previously (Jiu et al., 1999). For in vivo treatments with IL-2 complex, 8-week-old C57BL/6 female mice were treated with IL-2 complex (IL2c) formed of recombinant IL-2 (R&D, Abingdon, UK) and anti-IL-2 antibody (clone JES5-1A9; BioXcell, West Lebanon, NH). These materials were prepared at a 1:10 ratio of IL-2 to anti-IL-2 (2.5 μg:25 μg) in sterile PBS for i.p. delivery, as described previously (Pelley et al., 2016). Mice were challenged with two i.p. doses of IL2c on days −7 and 0 before SIA was initiated.

Human Study Subjects
Peripheral blood from RA patients (n = 59) and healthy controls (n = 21) was analyzed using flow cytometry for ILC2s and their demographic and disease activity by disease activity score 28 (DAS28)-ESR, in which we counted the number of tender joints and swollen joints and recorded general health scale by patient for themselves and measured erythrocyte sedimentation rate (ESR) in blood. The samples of synovial tissues were obtained from patients with active RA using needle arthroscopy. All analyses of human material were performed in full agreement with institutional guidelines and with the approval of the ethics committee of the University Hospital Erlangen. Informed consent and permission to use the obtained data for research were obtained from all subjects enrolled in the study.

Flow Cytometry
For detection of ILC2s in human blood samples, cells were stained with biotinylated CD11c (332732; BioLegend), CD123 (306004; BioLegend), CD14 (367106; BioLegend), CD34 (343524; BioLegend), FcdR1 (13-5899-82; eBioscience), TCR ab (306704; BioLegend), TCR gd (331208; BioLegend), CD303 (orb114050; Biobyit), and CD94 (130-098-966; Milteny Biotech), followed by streptavidin–labeled Texas red (562318; BD Bioscience) and CD3 (17-0082-82; Milteny Biotech), CD4 (129004; BioLegend), and GATA3 (653804; BioLegend) (Figure S5A). For detection of ILC2s in mice, cells suspensions from blood, spleen, mesenteric lymph nodes, and lung were stained with biotinylated CD3e (100304; BioLegend), CD4 (100508; BioLegend), CD8a (100704; BioLegend), CD19 (1150504; BioLegend), CD11b (101204; BioLegend), and CD161 (108704; BioLegend) followed by streptavidin–labeled Texas red (562318; BD Bioscience) and CD45 (103108; BioLegend), CD69.2 (140322; BioLegend), KLRG1 (138426; BioLegend), ST2 (101001PE; BD Bioscience), and GATA3 (653806; BioLegend). Prior to staining with antibodies (Abs), a LIVE/DEAD Fixable Violet Dead Cell Stain Kit (Life Technologies) was used to exclude dead cells. For intracellular cytokine staining of ILC2s, total lymphocytes were incubated in vitro overnight with GATA3 AB. ILC2s were gated on CD45+ Lin−/−ICOS+ KLRG1+ ST2+ cells. The purity of ILC2 populations was determined by disease activity score 28 (DAS28)-ESR, in which we counted the number of tender joints and swollen joints and recorded general health scale by patient for themselves and measured erythrocyte sedimentation rate (ESR) in blood. The samples of synovial tissues were obtained from patients with active RA using needle arthroscopy. All analyses of human material were performed in full agreement with institutional guidelines and with the approval of the ethics committee of the University Hospital Erlangen. Informed consent and permission to use the obtained data for research were obtained from all subjects enrolled in the study.

Cell Reports 24, 169–180, July 3, 2018 177
(HyClone), 50 μM 2-mercaptoethanol, 1 mM sodium pyruvate (Life Technologies), non-essential amino acids (Life Technologies), and 20 mM HEPES (pH 7.4), plus various stimulants. Sorted ILC2s from the spleens of mice treated with mcIL-25 and mcIL-33 were stimulated with 50 ng/mL of IL-2, IL-7, IL-25, and IL-33 and 20 ng/mL TSLP to activate and expand ILC2s for 14 days before flow cytometric analysis or adoptive transfer experiments, as previously described (Duerr et al., 2016). Before the experiments, the expanded cells were analyzed using FACS again (Figure S5 E). For measurement of the expression of IL-1β, IL-6, IL-25, IL-33, and TNF-α, ELISA kits from Invitrogen Thermo Fisher Scientific were used. To analyze expression of Th serum cytokines, we used LEGENDplex (BioLegend) according to the manufacturer’s instructions. For measurement of IL-4 (562915; BioLegend) (Figure S5C), IL-5 (504311; BioLegend), and IL-13 (25-5941-82; eBioscience) expression on ILC2s by FACS, splenocytes were incubated for 4 hr with PMA (50 ng/mL) and ionomycin (1 μg/mL).

Adaptive Transfer Experiment For ILC2 cell adoptive transfer, donor mice were hydrodynamically injected with 4 μg of IL-25 mc and IL-33 mc for induction of ILC2s. Five days after plasmid injection, flow cytometry-purified donor splenic ILC2s were expanded in vitro (see Cell Cultures) before 1 × 10^7 cells intravenous (i.v.) injection into C57BL/6 or BALB/c/J mice. ILC2s were analyzed in the splenocytes of recipient mice post-ILC2 cell transfer. To examine the presence of ILC2s in the joints, we generated bone marrow chimeras. We isolated bone marrow from Roracre TdTomato/flx/flx mice and transferred 1 × 10^7 cells of femoral and tibial bone marrow monocytes (BMMs) into irradiated naive C57BL/6 mice (10 Gy). Eight weeks after the transfer of BMMs, 150 μL serum of K/BxN mice was injected to initiate arthritis. Mice were sacrificed 8 days later, and tibial bones and paws were analyzed histologically.

Histology For histological analysis, tarsal joints of hind paws and tibial bones were fixed in 4% formalin for 12 hr and decalcified in EDTA (Sigma-Aldrich). Serial paraffin sections (2 μm) were stained for H&E and tartrate-resistant acid phosphatase (TRAP) using a Leukocyte Acid Phosphatase Kit (Sigma-Aldrich) according to the manufacturer’s instructions. Inflammation, bone destruction, and osteoclast numbers were quantified using a microscope (Nikon) equipped with a digital camera and an image analysis system for performing histomorphometry (OsteoMeasure; OsteoMetrics). For histological analysis in bone marrow chimera experiment using Roracre TdTomato/flx/flx mice, we stained ILC2s using Abs against IL-17RB (sc211754; Santa Cruz), CD3ε (17-0031; eBioscience), and DAPI. For other histological analyses, we stained ILC2s using Abs against IL17RB, ST2 (3636; ProSci), CD3ε, CD11b (1124; R&D Systems), CD11c (ab33483; Abcam), B220 (14-0452; eBioscience), Ly6G (MAB1037; R&D Systems), and DAPI.

Statistical Analysis Statistical analyses were performed using Student’s t test, the Mann-Whitney test, and one-way or two-way ANOVA followed by Tukey’s multiple-comparison post-test. For all experiments, p values are indicated as *p < 0.05, **p < 0.01, or ***p < 0.001. Graph generation and statistical analyses were performed using Prism version 6c software (GraphPad).


